Navigation Links
Visions: Broderick says Wisconsin should be in top third in venture capital

, itself, in some ways has a reputation, earned or not, of being a high-tax state. In general, some people on the coasts and elsewhere hear that, and consciously or subconsciously factor that into their decisions of where they are going to spend time.

WTN: Do you think we're taking the right approach in trying to build the angel infrastructure first, believing that will lead to mo......

Full article >>>
'"/>

Source:wistechnology.com By Joe Vanden Plas 06/13/07


Page: 1 2 3 4

Related biology technology :

1. Visions: Chicago software exec Jason Fried breaks (almost) all the rules
2. Visions: Preizler offers insurers perspective on healthcare IT
3. Visions: Matheys says CIO role is good training for executive suite
4. Visions: IT exec says CIOs must be ready to help companies ramp up trade
5. Visions: Innovating like Madonna and Willie Nelson (and Steve Jobs)
6. Visions: Wade offers straight talk on e-medical records
7. Visions: Benson touts embedded innovation
8. Visions: Carbone bullish on Wisconsin venture capital
9. Visions: Rimas Buinevicius, CEO of Sonic Foundry
10. WTN Visions: Convergence is changing business
11. To be a player in the "Knowledge Economy," Wisconsin needs more tech workers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Visions Broderick says Wisconsin should top third venture capital

Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2